Replies to post #146542 on Biotech Values

[mcbio]

No, because there are already several companies known to be pursuing Rituxan FoB’s.

Yeah, but MNTA is apparently the only one pursuing fully-interchangeable versions of those FoBs, which could clearly differentiate them from the competition.

[DewDiligence]

Boehringer-Ingelheim starts phase-3 trial of Rituxan FoB in RA:

http://www.clinicaltrials.gov/ct2/show/NCT01682512

Thanks to ‘biosimilarz’ for this find.